資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/30981
|
| 標題: | Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer |
| 作者: | Leung, Henry W. C.
Chan, Agnes L. F.
Muo, Chih-Hsin |
| 貢獻者: | China Med Univ, An Nan Hosp, Dept Radiat Therapy
Chia Nan Univ Pharm & Sci, Dept Informat Management
China Med Univ, An Nan Hosp, Dept Pharm
Chia Nan Univ Pharm & Sci, Dept Pharm
China Med Univ Hosp, Management Off Hlth Data |
| 關鍵字: | cost-effectiveness
economic evaluation
locally advanced pancreatic cancer
stereotactic body radiotherapy |
| 日期: | 2016-05 |
| 上傳時間: | 2018-01-18 11:39:09 (UTC+8) |
| 出版者: | Elsevier |
| 摘要: | Purpose: The purpose of this study was to evaluate the cost-effectiveness of gemcitabine plus modern radiotherapy versus gemcitabine alone in the treatment of locally advanced pancreatic cancer in Taiwan. Methods: A Markov decision-analytic model was performed to compare the cost-effectiveness of 3 treatment regimens; gemcitabine alone (gem-alone), gemcitabine plus intensity-modulated radiotherapy (gem-IMRT), and gemcitabine plus stereotactic body radiotherapy (gem-SBRT). Patients transitioned between 5 health states: stable disease, local progression, distant metastasis, local and distant metastasis, and death. Findings: The incremental cost-effectiveness ratio for gem-IMRT and gem-SBRT compared with gem alone were NT$27,120,168 and NT$2,145,683 per quality-adjusted life-year gained, respectively. A willingness to pay threshold of 3 times the per capita gross domestic product was adopted according to the definition of the World Health Organization. The Taiwan per capita gross domestic product in 2015 was NT$673,920 (US$22,464; 1 NT$ = US$0.03333 in Taiwan); thus, a threshold was considered as NT $2,021,760 (US$67,392). The Monte-Carlo simulation found that the probability of cost-effectiveness at a willingness to pay threshold of NT$2,021,760 per quality-adjusted life-year was 0% chance for gem-IMRT and 50% for gem-SBRT. Implications: This study indicated that gem-IMRT or gem-SBRT in locally advanced pancreatic cancer is not cost-effective at a willingness to pay as defined by World Health Organization guideline in Taiwan. (C) 2016 Elsevier HS Journals, Inc. All rights reserved. |
| 關聯: | Clinical Therapeutics, v.38 n.5, pp.1174-1183 |
| 顯示於類別: | [藥學系(所)] 期刊論文
[資訊管理系] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 1455 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
